Creo Medical Group’s (CREO) House Stock Rating Reiterated at Shore Capital Group

Shore Capital Group reiterated their house stock rating on shares of Creo Medical Group (LON:CREO) in a research note published on Thursday,Digital Look reports.

Creo Medical Group Stock Up 9.3%

Shares of CREO opened at GBX 13.25 on Thursday. The firm has a 50 day simple moving average of GBX 13.63 and a two-hundred day simple moving average of GBX 12.02. The company has a debt-to-equity ratio of 6.90, a current ratio of 5.28 and a quick ratio of 2.19. Creo Medical Group has a one year low of GBX 9.22 and a one year high of GBX 18.50. The company has a market cap of £54.65 million, a P/E ratio of -13.25 and a beta of 1.22.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.